

Supplementary Table S1

	In-hospital Death		<i>P</i> value
	No (n = 73)	Yes (n = 90)	
Demographics and comorbidity			
Age (years)	61.41 [54.70-70.35]	71.90 [65.97-74.69]	< 0.0001
Male sex	52 (71.2%)	62 (68.9%)	0.8638
Ethnicity			< 0.0001
Caucasian	51 (69.9%)	87 (96.7%)	
Latin	16 (21.9%)	1 (1.1%)	
Other	1 (1.4%)	1 (1.1%)	
Smoker status			0.0030
Never	500 (68.5%)	39 (43.3%)	
Former smoker	16 (21.9%)	41 (45.6%)	
Current smoker	4 (5.5%)	8 (8.9%)	
Obesity	18 (25.7%)	30 (34.9%)	0.2282
Charlson Index	0.00 [0.00-1.00]	2.00 [1.00-3.00]	< 0.0001
Hypertension	30 (41.1%)	69 (76.7%)	< 0.0001
Diabetes mellitus	14 (19.2%)	43 (47.8%)	0.0001
COPD	2 (2.7%)	19 (21.1%)	0.0003
Obstructive sleep apnea	6 (8.2%)	13 (14.6%)	0.2307
Heart failure	3 (4.1%)	15 (16.7%)	0.0119
Clinical presentation			
Duration of symptoms (days)	7 [5-10]	6 [4-8]	0.0175
Respiratory rate > 20 breaths/min	25 (35.2%)	52 (58.4%)	0.0042
Altered mental status	3 (4.2%)	14 (15.7%)	0.0202
C-reactive protein (mg/L)	133.0 [65.1-221.2]	106.0 [41.0-186.5]	0.1236
D-dimer (ng/mL)	719 [400-1280]	1015 [630-1750]	0.0349
Lymphocyte count (cells/ μ L)	850 [700-1130]	780 [500-1140]	0.1896
SaO ₂ /FiO ₂	419 [328.6-442.9]	378.6 [186.3-428.6]	0.0174
Treatments received			
Lopinavir/ritonavir	48 (65.8%)	56 (62.2%)	0.7434
Hydroxychloroquine	69 (94.5%)	76 (84.4%)	0.0469
Remdesivir	2 (2.7%)	0 (0.0%)	0.2015
Corticosteroids	57 (78.1%)	57 (63.3%)	0.0583
Tocilizumab	31 (42.5%)	15 (16.7%)	0.0004
Antibiotic use	67 (98.5%)	83 (93.3%)	0.1402
Beta-lactamic	55 (82.1%)	64 (71.9%)	0.1832
Quinolone	11 (16.4%)	16 (18.2%)	0.8332
Azithromycin	47 (69.1%)	47 (52.8%)	0.0488
Prone position			
Yes	34 (46.6%)	26 (28.9%)	0.0229

Continuous variables are expressed as median and interquartile range [Q1-Q3]. Categorical variables are expressed as number and percentage.

COPD: Chronic obstructive pulmonary disease